A Michigan Medicine study finds that people with two pediatric-onset neurodevelopmental disorders are prescribed opioids at significantly higher rates than those without the conditions, raising concerns over addiction, overdose and mental health issues.

Researchers analyzed prescriptions of opioids from private insurance claims of over 22,000 patients with cerebral palsy or spina bifida, and more than 930,000 patients without the conditions.

They found that oral morphine equivalents, derived from medications such as oxycodone, codeine and morphine, were prescribed to patients with cerebral palsy and spina bifida at a rate up to five times higher than patients who do not have those conditions. The higher prescription patterns spanned across people with no pain, isolated and chronic pain, according to results published in Heliyon.

“Our findings are of great concern, given the known links between persistent opioid use and psychiatric conditions, as well as with overdose mortality,” said Mark Peterson, Ph.D., M.S., lead author of the paper and an associate professor of physical medicine and rehabilitation at University of Michigan Medical School.

Chronic pain is the most commonly reported symptom among patients with cerebral palsy, a neurological condition caused by abnormalities in the brain, and spina bifida, a neural tube defect that can damage the spinal cord and nerves. Pain in these individuals may arise from several issues, including muscle spasticity, arthritis and invasive surgical procedures.

Previous studies found that more than 40% of all Medicaid beneficiaries with a disability took opioid pain relievers, with more than 20% reporting chronic opioid use. The research team raises concerns over whether long-term opioid use is appropriate for the treatment of non-cancer-related chronic pain.

Future studies must examine the effectiveness of non-opioid pain medications and alternative pain management strategies for adults living with cerebral palsy and spina bifida, says co-author Edward Hurvitz, M.D., chair of the U-M Health Department of Physical Medicine and Rehabilitation and a professor at U-M Medical School.

“Improving clinical pain screening strategies and developing efficient referral resources for appropriate pain management may help reduce the burden of opioid addiction and overdose in these populations by matching treatments to underlying pain mechanisms,” Hurvitz said.

Additional authors include: Neil Kamdar, M.A., Jeidi J. Haapala, M.D., Chad Brummett, M.D., all of Michigan Medicine

This research was developed in part under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR #90RTHF0001-01-00).



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is frozen water?

Explore More

Long-term follow up pinpoints side effects of treatments for prostate cancer patients

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse

Potential therapy may boost chemoimmunotherapy response in bladder cancer

Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancerinvestigators. The findings,

Researchers identify drug resistance factors for advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable